Herbal Medicine By China’s Tasly First TCM In Western Trials
This article was originally published in PharmAsia News
Traditional Chinese medicine appears to be gaining greater acceptance in the Western, although there is widespread agreement on a need for standardization. China's Tasly Pharmaceutical has submitted an herbal drug, danshen, already available in much of Africa for treating a variety of diseases, is undergoing clinical trials in the European Union and in the United States where the FDA approved it as the first TCM for testing. The lack of scientific proof for the effectiveness of herbal treatments, some used in other countries for hundreds of years, has stymied their acceptance by Western drug makers and nations. U.S. and Chinese agree globalization will come only after TCM compounds are subjected to standardization. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.